Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA)
Clinical trial NCT01392326 · COMPLETED
Trial details
- NCT number
- NCT01392326
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2011-09-01
- Primary completion
- 2014-10-01
- Enrollment
- 606
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.